Skip to main content

Table 3 Temperature analyses and outcomes of included patients, according to the methods of cooling. Data are expressed as count (%) or median (25th–75th percentiles)

From: Intravascular versus surface cooling for targeted temperature management after out-of-hospital cardiac arrest: an analysis of the TTH48 trial

  IC (n = 218) SFC (n = 134)
Primary outcome
 CPC 3–5 at 6 months 69 (32%) 51 (38%)
Secondary outcomes
 Mortality at 6 months 65 (29%) 43 (32%)
Adverse events
 Any adverse event 203 (93%) 118 (88%)
 Pneumonia 106 (49%) 56 (42%)
 Other infections 75 (34%) 54 (40%)
 Any bleeding 24 (11%) 16 (12%)
 RBC transfusion 20 (9%) 15 (11%)
 Seizure/myoclonus localized 27 (12%) 18 (13%)
 Seizure/myoclonus globalized 39 (18%) 25 (19%)
 Severe circulation failure 13 (6%) 15 (11%)
 Arrhythmias 105 (48%) 50 (37%)*
 Severe (VT/VF or unstable despite treatment) 21 (10%) 19 (14%)
 New cardiac arrest requiring CPR 7 (3%) 5 (4%)
 Renal replacement therapy 13 (6%) 14 (10%)
 Hyperglycemia 169 (78%) 113 (83%)
 Hypernatremia 21 (10%) 24 (18%)*
 Hypokalemia 88 (40%) 38 (28%)*
Resource use
 ICU length of stay (days) 5 [3–7] 6 [3–9]
  1. IC intravascular catheter, SFC surface cooling, RBC red blood cells. $p < 0.001; *p < 0.05; p < 0.1